O6-Benzylguanine and Temozolomide in Combination With Genetically Modified Peripheral Blood Stem Cells in Newly Diagnosed Glioblastoma Multiforme

This study has suspended participant recruitment.
(Drugs unavailable)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Stanton Gerson MD, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01269424
First received: December 31, 2010
Last updated: July 21, 2014
Last verified: July 2014
  Purpose

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. O6-benzylguanine may help temozolomide work better by making tumor cells more sensitive to the drug. Giving genetically modified peripheral blood stem cells during or after treatment may prevent side effects caused by chemotherapy.

PURPOSE: This clinical trial studies O6-benzylguanine and temozolomide in combination with genetically modified peripheral blood stem cells in treating patients with newly diagnosed glioblastoma multiforme.


Condition Intervention Phase
Brain and Central Nervous System Tumors
Biological: MGMTP140K-encoding retroviral vector
Drug: O6-benzylguanine
Drug: temozolomide
Other: laboratory biomarker analysis
Procedure: autologous hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Radiation: radiation therapy
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: O6-Benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis

Resource links provided by NLM:


Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:
  • Feasibility of infusing autologous P140K MGMT-transduced hematopoietic progenitors into patients with GBM [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
    Patients will be assessed for clinical symptoms and side-effects from time of treatment until protocol is stopped due to toxicity, progression, patient choice, or patient election to enroll on new therapeutic option.

  • Safety (grade IV toxicity) [ Time Frame: up to 5 years ] [ Designated as safety issue: Yes ]
    CTCAE v 4.0 will be used as the criteria for evaluating infusion-related events.


Secondary Outcome Measures:
  • Successful transduction rate [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    Quantitate P140K transduced hematopoietic cells from the bone marrow and peripheral blood in patients infused with P140K transduced CD34 progenitors

  • To evaluate the in vivo enrichment of P140K expressing hematopoietic cells by repeated treatments of BG and TMZ [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    To evaluate the in vivo enrichment of P140K expressing hematopoietic cells by repeated treatments of BG and TMZ

  • Progression-free [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
    Progression-free survival defined as the time interval between the date of initial histological diagnosis and the date of disease progression or death, whichever comes first

  • Number of patients with radiological progression [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
    New tumor or increased tumor size on T1WI + Gd of > 25% as measured by the sum of two perpendicular diameters compared to the smallest measurements ever recorded for the same lesion by the same technique.

  • Overall Survival [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
    From the date of enrollment to death, last contact or last tumor assessment before further anti-tumor therapy, assessed up to 5 years.


Estimated Enrollment: 18
Study Start Date: December 2010
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Cohort 1
LV gene transfer after concurrent chemo-radiotherapy
Biological: MGMTP140K-encoding retroviral vector Drug: O6-benzylguanine Drug: temozolomide Other: laboratory biomarker analysis Procedure: autologous hematopoietic stem cell transplantation Procedure: in vitro-treated peripheral blood stem cell transplantation Radiation: radiation therapy
Active Comparator: Cohort 2
LV gene transfer prior to concurrent chemo-radiotherapy
Biological: MGMTP140K-encoding retroviral vector Drug: O6-benzylguanine Drug: temozolomide Other: laboratory biomarker analysis Procedure: autologous hematopoietic stem cell transplantation Procedure: in vitro-treated peripheral blood stem cell transplantation Radiation: radiation therapy
Active Comparator: Cohort 3
Intra patient dose escalation of TMZ in patients with evidence of P140K marked cells
Biological: MGMTP140K-encoding retroviral vector Drug: O6-benzylguanine Drug: temozolomide Other: laboratory biomarker analysis Procedure: autologous hematopoietic stem cell transplantation Procedure: in vitro-treated peripheral blood stem cell transplantation Radiation: radiation therapy

Detailed Description:

OBJECTIVES:

Primary

  • To evaluate the feasibility of introducing and expressing P140K MGMT cDNA from a lentiviral-based provirus in autologous hematopoietic stem cells harvested from GBM patients.
  • To assess the safety associated with infusion of autologous hematopoietic stem cells transduced ex vivo with a lentiviral vector expressing P140K MGMT in patients with GBM.

Secondary

  • To determine whether any patients who receive P140K MGMT-transduced CD34 cells tolerate O6-benzylguanine (BG) and dose-escalated temozolomide (TMZ) without myelosuppression.
  • To evaluate the ability to detect P140K-transduced BG and TMZ-resistant hematopoietic cells from the bone marrow and peripheral blood in patients infused with P140K-transduced CD34 progenitors.
  • To evaluate the feasibility of in vivo enrichment of P140K-expressing hematopoietic cells by repeated treatments of BG and TMZ at doses that appear therapeutic for GBM.
  • To evaluate tumor response, progression-free survival, and overall survival.

OUTLINE: Patients are assigned to 1 of 3 treatment cohorts.

  • Cohort 1 (LV P140K MGMT gene transfer after concurrent chemoradiotherapy): Patients receive radiotherapy (60cGy in 30 2cGy daily doses) and TMZ 75mg/m2 /daily for 6 weeks, cell infusion at week 7 (T0) followed by BG 120 mg/m2 intravenous infusion over 1h and TMZ 50 mg/m2/day x 5 days, every 28 days (starting on T+28) for 6 cycles.
  • Cohort 2 (LV P140K MGMT gene transfer prior to concurrent chemoradiotherapy): Patients receive BG 120mg/m2 intravenous infusion over 1h and TMZ 400 mg/m2 one dose given on day T-2 or T-3 days prior to cell infusion, followed within 72-96 hours by radiotherapy (60cGy in 30 2cGy daily doses) and concurrent BG + TMZ at 50 mg/m2/day x 5 days, every 28 days,starting on T+28 for a total of 7 cycles of BG + TMZ.
  • Cohort 3 (intra-patient dose escalation of TMZ in patients with evidence of P140K-marked cells): Dose escalation of TMZ in patients with evidence of P140K marked cells in vivo given as described above for cohort 1 or cohort 2. After completion of radiotherapy, patients will receive BG + TMZ at 50 mg/m2/day x 5 days. Patients not experiencing any grade 3 toxicity will be increased to the next TMZ dose level of 65 mg/m2/day x 5. Subsequent dose escalation without grade 3 toxicity will be 80 mg/m2/day, 100 mg/m2/day, 120mg/m2/day and 140 mg/m2/day x 5. If at subsequent cycles a grade 3 or greater hematologic toxicity occurs, the dose level for the next cycle will be reduced one level.

Blood samples are collected periodically for replication-competent lentivirus detection and other laboratory biomarker studies.

After completion of study therapy, patients are followed up every 2 months.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically confirmed, newly diagnosed, supratentorial GBM who have undergone gross total tumor resections or near gross total resection (resection of >90% of enhancing tumor demonstrated by MRI) are eligible up to their third post-operative week. Patients with infratentorial disease, multifocal or leptomeningeal disease will be excluded. In general, patients will not have > 1 cm residual measurable or evaluable disease after surgical tumor resection.
  • Patients aged 18-70. Patients >70 will be excluded due to difficulties in mobilization and collection of adequate numbers of peripheral progenitors.
  • ECOG performance status 0-2 or Karnofsky ≥ 60.
  • Patients must have received no myelosuppressive chemotherapy prior to the diagnosis of GBM.
  • Life expectancy of at least 12 weeks.
  • Adequate hematologic (ANC ≥ 1000/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9.5 , hepatic (Bilirubin ≤ 2.0 mg/dl, AST and ALT less than or equal to 3 times upper limit of normal, prothrombin time <1.2 times normal), and renal (Serum creatinine ≤ 2.0 mg/dl or Creatinine Clearance ≥ 60mL/min/1.73 m2 for subjects with serum creatinine levels above institutional normal) . These tests will be repeated within 2 weeks of treatment with BG and TMZ, and must meet the same criteria.
  • EKG without evidence of acute cardiac disease.
  • Post-operative steroids are tapered to ≤ 24 mg decadron/d
  • Patients of child-bearing potential must be using single barrier contraception
  • Willingness and ability to provide informed consent.

Exclusion criteria:

  • Medical condition associated with immunosuppression, active infection or medical illness which may jeopardize patient safety.
  • HIV seropositivity. This exclusion is included for two reasons. First, there is evidence of decreased marrow reserve in HIV+ patients and antiviral treatment is associated with myelosuppression. Thus, drug treatment designed to be myelosuppressive may be more toxic in this patient population. Second, extensive laboratory culturing of the bone marrow and peripheral blood progenitor cells is required. No preclinical samples which are HIV+ have been evaluated with the gene transfer modality proposed and thus the feasibility and safety of gene transfer and selection in HIV+ samples cannot yet be advocated. Such studies are planned so as to not preclude HIV+ patients in later studies.
  • Pregnant or lactating women. There is data to indicate that TMZ is teratogenic and carcinogenic. Thus, its use in pregnant women would confer unnecessary risk to the fetus.
  • Patients with symptomatic pulmonary disease and other severe co-morbid conditions
  • Prior chemotherapy (including gliadel wafers) or hematopoietic cell transplantation.
  • Inability to undergo repeated MRI evaluation.
  • Prior diagnosis of malignant disease within a three year period with the exception of surgically cured basal cell carcinoma or carcinoma in situ of the cervix
  • Mental incapacity or psychiatric illness preventing informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01269424

Locations
United States, Ohio
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5047
Sponsors and Collaborators
Stanton Gerson MD
Investigators
Principal Investigator: Andrew E. Sloan, MD Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Stanton Gerson MD, Director, Case Comprehensive Cancer Center, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT01269424     History of Changes
Other Study ID Numbers: CASE6307, NCI-2011-02566, 8274, U01CA062502
Study First Received: December 31, 2010
Last Updated: July 21, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Case Comprehensive Cancer Center:
adult giant cell glioblastoma
adult glioblastoma
adult gliosarcoma

Additional relevant MeSH terms:
Glioblastoma
Nervous System Neoplasms
Central Nervous System Neoplasms
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Temozolomide
Dacarbazine
O(6)-benzylguanine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 20, 2014